Home › Companies › OLEMA PHARMACEUTICALS INC. › 2024-2025

OLEMA PHARMACEUTICALS INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and OLEMA PHARMACEUTICALS INC.’s Form 8-K, filed 2025-06-13 (Item 5.07 on EDGAR). Page generated 02 October 2026.

9Reported items
155Asset managers
902Fund votes
2025-06-10Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore OLEMA PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by OLEMA PHARMACEUTICALS INC.

These tallies are OLEMA PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-13 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

OLEMA PHARMACEUTICALS INC. — official shareholder meeting results, meeting held 2025-06-10
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Cynthia Butitta	44,675,129	--	--	11,733,848	6,361,695	Majority: yes
Elect Director: Cyrus Harmon, Ph.D.	43,838,514	--	--	12,570,463	6,361,695	Majority: yes
Elect Director: Graham Walmsley, M.D., Ph.D.	44,120,432	--	--	12,288,545	6,361,695	Majority: yes
Proposal 2: Advisory Vote on Executive Compensation Final Voting Results	54,057,177	2,297,482	54,317	--	6,361,695	Majority: yes
Proposal 3: Ratification of Selection of Independent Registered Public Accounting Firm Final Voting Results	62,732,079	24,064	14,528	--	--	Majority: yes

Source: OLEMA PHARMACEUTICALS INC., Form 8-K, filed with the SEC on 2025-06-13 — read the filing on EDGAR.

How asset managers voted at the OLEMA PHARMACEUTICALS INC. 2024-2025 meeting

Each item below shows how the 155 asset managers that disclosed a OLEMA PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of OLEMA PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 54,057,177AGAINST: 2,297,482

OLEMA PHARMACEUTICALS INC.’s own tally for this item (“Proposal 2: Advisory Vote on Executive Compensation Final Voting Results”): 54,057,177 for, 2,297,482 against, per its Form 8-K filed 2025-06-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 68,333,065 outstanding shares: 79% for, 3% against (82% of the company cast a for/against vote).

The 147 asset managers below cast 97% of the shares they voted on this item FOR (46,972,469 for, 1,210,442 against).

FOR 97%

FOR: 46,972,469 (97.5%)AGAINST: 1,210,442 (2.5%)

Largest asset managers voting on “APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.” at OLEMA PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Vote
Paradigm Biocapital Advisors LP	5,785,104	0	For
BVF INC/IL	5,295,893	0	For
Deep Track Capital, LP	3,442,833	0	For
FRANKLIN ADVISERS INC	3,011,969	0	For
BlackRock	2,961,308	1,111	For
Vanguard	2,925,039	0	For
Logos Global Management LP	2,508,114	0	For
MPM BioImpact LLC	2,450,282	0	For
Lightspeed Management Company, L.L.C.	1,930,894	0	For
PICTET ASSET MANAGEMENT SA	1,747,813	0	For
FRANKLIN STRATEGIC SERIES	1,665,389	0	For
Vivo Capital, LLC	1,505,862	0	For
Woodline Partners LP	1,466,656	0	For
Point72	1,250,735	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,096,185	0	For
Citadel	1,048,722	0	For
Fidelity	995,213	0	For
Charles Schwab	717,662	0	For
Dimensional	0	694,491	Against
Victory Capital	680,412	0	For
State Street	645,406	73	For
Nuveen	486,236	0	For
TIAA	483,544	0	For
JACOBS LEVY EQUITY MANAGEMENT, INC	399,531	0	For
Northern Trust	326,924	0	For

Showing the 25 largest of 147 asset managers. See all 147 in the interactive database.

2. Election of the three nominees for Class II director named in the accompanying proxy statement to hold office until the Company's 2028 Annual Meeting of Stockholders and until their successors have been duly elected and qualified: Cynthia Butitta

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

79% Majority: yes · of votes cast

FOR 79%WITHHELD 21%

FOR: 44,675,129WITHHELD: 11,733,848

OLEMA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Cynthia Butitta”): 44,675,129 for, 11,733,848 withheld, per its Form 8-K filed 2025-06-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 68,333,065 outstanding shares: 65% for, 17% withheld (83% of the company cast a for/withheld vote).

The 48 asset managers below cast 100% of the shares they voted on this item FOR (8,504,933 for, 0 against).

FOR 87%13%

FOR: 8,504,933 (86.9%)ABSTAIN: 1,287,594 (13.1%)

Largest asset managers voting on “Election of the three nominees for Class II director named in the accompanying proxy statement to hold office ” at OLEMA PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	2,884,411	0	For
FRANKLIN STRATEGIC SERIES	1,665,389	0	For
BlackRock	1,574,360	0	For
Fidelity	968,985	0	For
Dimensional	0	603,916	Abstain
TIAA	483,544	0	For
Charles Schwab	358,831	0	For
Victory Capital	0	329,866	Abstain
Equitable	74,094	67,160	For
RBB FUND, INC.	109,871	0	For
Dunham Funds	86,147	0	For
Thrivent	0	70,595	Abstain
Goldman Sachs	66,964	0	For
VALUED ADVISERS TRUST	0	56,137	Abstain
Lincoln Financial	40,245	5,674	For
Northern Trust	45,647	0	For
Invesco	35,829	0	For
BRIDGEWAY FUNDS INC	0	25,000	Abstain
Global X	24,140	0	For
AIG/SunAmerica	0	20,881	Abstain
Voya	20,681	0	For
Pacific Life	17,666	0	For
ETFis Series Trust I	0	16,740	Abstain
John Hancock	0	15,571	Abstain
Bridge Builder Trust	15,473	0	For

Showing the 25 largest of 48 asset managers. See all 48 in the interactive database.

3. Election of the three nominees for Class II director named in the accompanying proxy statement to hold office until the Company's 2028 Annual Meeting of Stockholders and until their successors have been duly elected and qualified: Cyrus Harmon, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

78% Majority: yes · of votes cast

FOR 78%WITHHELD 22%

FOR: 43,838,514WITHHELD: 12,570,463

OLEMA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Cyrus Harmon, Ph.D.”): 43,838,514 for, 12,570,463 withheld, per its Form 8-K filed 2025-06-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 68,333,065 outstanding shares: 64% for, 18% withheld (83% of the company cast a for/withheld vote).

The 48 asset managers below cast 100% of the shares they voted on this item FOR (8,466,368 for, 0 against).

FOR 86%14%

FOR: 8,466,368 (86.5%)ABSTAIN: 1,326,159 (13.5%)

Largest asset managers voting on “Election of the three nominees for Class II director named in the accompanying proxy statement to hold office ” at OLEMA PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	2,884,411	0	For
FRANKLIN STRATEGIC SERIES	1,665,389	0	For
BlackRock	1,574,360	0	For
Fidelity	968,985	0	For
Dimensional	0	603,916	Abstain
TIAA	483,544	0	For
Charles Schwab	358,831	0	For
Victory Capital	0	329,866	Abstain
Equitable	141,254	0	For
RBB FUND, INC.	109,871	0	For
Dunham Funds	86,147	0	For
Thrivent	0	70,595	Abstain
Goldman Sachs	66,964	0	For
VALUED ADVISERS TRUST	0	56,137	Abstain
Lincoln Financial	10,645	35,274	Abstain
Northern Trust	0	45,647	Abstain
Invesco	35,829	0	For
BRIDGEWAY FUNDS INC	0	25,000	Abstain
Global X	24,140	0	For
AIG/SunAmerica	0	20,881	Abstain
Voya	0	20,681	Abstain
Pacific Life	17,666	0	For
ETFis Series Trust I	0	16,740	Abstain
John Hancock	0	15,571	Abstain
Bridge Builder Trust	15,473	0	For

Showing the 25 largest of 48 asset managers. See all 48 in the interactive database.

4. Election of the three nominees for Class II director named in the accompanying proxy statement to hold office until the Company's 2028 Annual Meeting of Stockholders and until their successors have been duly elected and qualified: Graham Walmsley, M.D., Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

78% Majority: yes · of votes cast

FOR 78%WITHHELD 22%

FOR: 44,120,432WITHHELD: 12,288,545

OLEMA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Graham Walmsley, M.D., Ph.D.”): 44,120,432 for, 12,288,545 withheld, per its Form 8-K filed 2025-06-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 68,333,065 outstanding shares: 65% for, 18% withheld (83% of the company cast a for/withheld vote).

The 48 asset managers below cast 100% of the shares they voted on this item FOR (8,465,536 for, 0 against).

FOR 86%14%

FOR: 8,465,536 (86.4%)ABSTAIN: 1,326,991 (13.6%)

Largest asset managers voting on “Election of the three nominees for Class II director named in the accompanying proxy statement to hold office ” at OLEMA PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	2,884,411	0	For
FRANKLIN STRATEGIC SERIES	1,665,389	0	For
BlackRock	1,574,360	0	For
Fidelity	968,985	0	For
Dimensional	0	603,916	Abstain
TIAA	483,544	0	For
Charles Schwab	358,831	0	For
Victory Capital	0	329,866	Abstain
Equitable	74,094	67,160	For
RBB FUND, INC.	109,871	0	For
Dunham Funds	86,147	0	For
Thrivent	0	70,595	Abstain
Goldman Sachs	66,964	0	For
VALUED ADVISERS TRUST	0	56,137	Abstain
Lincoln Financial	10,645	35,274	Abstain
Northern Trust	45,647	0	For
Invesco	35,829	0	For
BRIDGEWAY FUNDS INC	0	25,000	Abstain
Global X	24,140	0	For
AIG/SunAmerica	0	20,881	Abstain
Voya	20,681	0	For
Pacific Life	17,666	0	For
ETFis Series Trust I	0	16,740	Abstain
John Hancock	0	15,571	Abstain
Bridge Builder Trust	15,473	0	For

Showing the 25 largest of 48 asset managers. See all 48 in the interactive database.

5. RATIFICATION OF THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2025.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 62,732,079AGAINST: 24,064

OLEMA PHARMACEUTICALS INC.’s own tally for this item (“Proposal 3: Ratification of Selection of Independent Registered Public Accounting Firm Final Voting Results”): 62,732,079 for, 24,064 against, per its Form 8-K filed 2025-06-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 68,333,065 outstanding shares: 92% for, 0.1% against (92% of the company cast a for/against vote).

The 46 asset managers below cast 100% of the shares they voted on this item FOR (9,729,395 for, 0 against).

FOR 100%

FOR: 9,729,395 (100.0%)

Largest asset managers voting on “RATIFICATION OF THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS THE COM” at OLEMA PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Vote
Vanguard	2,884,411	For
FRANKLIN STRATEGIC SERIES	1,665,389	For
BlackRock	1,574,360	For
Fidelity	968,985	For
Dimensional	603,916	For
TIAA	483,544	For
Charles Schwab	358,831	For
Victory Capital	329,866	For
Equitable	141,254	For
RBB FUND, INC.	109,871	For
Dunham Funds	86,147	For
Thrivent	70,595	For
Goldman Sachs	66,964	For
Lincoln Financial	45,919	For
Northern Trust	45,647	For
Invesco	35,829	For
BRIDGEWAY FUNDS INC	25,000	For
Global X	24,140	For
AIG/SunAmerica	20,881	For
Voya	20,681	For
Pacific Life	17,666	For
ETFis Series Trust I	16,740	For
John Hancock	15,571	For
Bridge Builder Trust	15,473	For
Jackson National	13,179	For

Showing the 25 largest of 46 asset managers. See all 46 in the interactive database.

6. 14A Executive Compensation Approval, on an advisory basis, of the compensation of the Company's named executive officers.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

96% Majority: yes · of votes cast

FOR 96%

FOR: 54,057,177AGAINST: 2,297,482

The 3 asset managers below cast 100% of the shares they voted on this item FOR (702,976 for, 0 against).

FOR 100%

FOR: 702,976 (100.0%)

Largest asset managers voting on “14A Executive Compensation Approval, on an advisory basis, of the compensation of the Company's named executiv” at OLEMA PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Vote
Pier Capital, LLC	506,958	For
RBB FUND, INC.	109,871	For
Dunham Funds	86,147	For

7. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

96% Majority: yes · of votes cast

FOR 96%

FOR: 54,057,177AGAINST: 2,297,482

The 3 asset managers below cast 71% of the shares they voted on this item FOR (139,737 for, 56,137 against).

FOR 71%AGAINST 29%

FOR: 139,737 (71.3%)AGAINST: 56,137 (28.7%)

Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at OLEMA PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Vote
JPMorgan	132,742	0	For
VALUED ADVISERS TRUST	0	56,137	Against
HC CAPITAL TRUST	6,995	0	For

8. Ratify Ernst & Young LLP as Auditors

AUDIT-RELATED

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (63,132 for, 0 against).

FOR: 63,132 (100.0%)

Largest asset managers voting on “Ratify Ernst & Young LLP as Auditors” at OLEMA PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
VALUED ADVISERS TRUST	56,137	0	0	0	For
HC CAPITAL TRUST	6,995	0	0	0	For

9. Advisory vote to approve named executive compensation

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 54,057,177AGAINST: 2,297,482

The 2 asset managers below cast 100% of the shares they voted on this item FOR (6,696,640 for, 0 against).

FOR 100%

FOR: 6,696,640 (100.0%)

Largest asset managers voting on “Advisory vote to approve named executive compensation” at OLEMA PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
Bain Capital Life Sciences Investors, LLC	6,696,640	0	0	0	For
Ikarian Capital, LLC	0	0	0	0	--

Largest OLEMA PHARMACEUTICALS INC. shareholders voting in 2024-2025

Ranked by the number of OLEMA PHARMACEUTICALS INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 68,333,065 shares outstanding at the time of that meeting.

Top OLEMA PHARMACEUTICALS INC. shareholders by shares voted, 2024-2025
#	Asset manager	% of shares outstanding
1	Paradigm Biocapital Advisors LP	8.47%
2	BVF INC/IL	7.75%
3	Deep Track Capital, LP	5.04%
4	FRANKLIN ADVISERS INC	4.41%
5	BlackRock	4.34%
6	Vanguard	4.28%
7	Logos Global Management LP	3.67%
8	MPM BioImpact LLC	3.59%
9	Lightspeed Management Company, L.L.C.	2.83%
10	PICTET ASSET MANAGEMENT SA	2.56%

Reported OLEMA PHARMACEUTICALS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

OLEMA PHARMACEUTICALS INC. beneficial owners on record for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
FMR LLC	14.63%	13G
JANUS HENDERSON GROUP PLC	10.40%	13G
Raymond Debbane	6.53%	13G
BlackRock	5.59%	13F
Logos Global Management LP	4.70%	13D
Franklin Templeton	4.41%	13F
Vanguard Group	4.20%	13F
Wellington Management	2.16%	13F
Dimensional Fund Advisors	1.93%	13F
Geode Capital	1.59%	13F

Percentages above are of 68,333,065 shares outstanding, as reported by OLEMA PHARMACEUTICALS INC. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from OLEMA PHARMACEUTICALS INC.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At OLEMA PHARMACEUTICALS INC.'s shareholder meeting held 2025-06-10, in the 2024-2025 proxy season, 155 asset managers reported how they voted in their SEC Form N-PX filings, covering 902 separate fund positions. Their filings are grouped here into 9 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS. — FOR was 96% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: OLEMA PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-06-13.

OLEMA PHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.